Mutual of America Capital Management’s Fate Therapeutics FATE Stock Holding History

Mutual of America Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-55,956	Closed	-$1.25M	–	1497
2022 Q3	$1.25M	Sell	55,956 -5,095	-8%	-$147K	0.02%	987
2022 Q2	$1.51M	Sell	61,051 -457	-0.7%	-$12.6K	0.02%	971
2022 Q1	$2.38M	Sell	61,508 -2,673	-4%	-$104K	0.03%	889
2021 Q4	$3.75M	Sell	64,181 -600	-0.9%	-$34K	0.04%	711
2021 Q3	$3.84M	Sell	64,781 -935	-1%	-$73.3K	0.04%	671
2021 Q2	$5.7M	Buy	65,716 +5,778	+10%	+$466K	0.06%	454
2021 Q1	$4.94M	Sell	59,938 -3,314	-5%	-$318K	0.05%	508
2020 Q4	$5.75M	Sell	63,252 -1,328	-2%	-$82.5K	0.07%	391
2020 Q3	$2.58M	Sell	64,580 -11,050	-15%	-$386K	0.03%	697
2020 Q2	$2.6M	Buy	+75,630	New	+$2.25M	0.04%	704

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mutual of America Capital Management's FATE Position: Q4 2022 in Review

Mutual of America Capital Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 55,956 shares — an estimated $1.25M sold.

Mutual of America Capital Management first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $5.75M in Q4 2020. 228 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

Mutual of America Capital Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
Mutual of America Capital Management sold 55,956 Fate Therapeutics shares in Q4 2022, an estimated $1.25M.
Mutual of America Capital Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
Mutual of America Capital Management's Fate Therapeutics position peaked at $5.75M in Q4 2020.
228 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Mutual of America Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.